← Leaderboards
Francisco A Uzal
University Of Pittsburgh At Pittsburgh
$1,415,271
Attributed
$3,800,677
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $433.8K · FY2009–24$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,800,677 · 5
By mechanism
R01$2,081,289 · 1
R21$1,719,388 · 4
Top collaborators
- Bruce A Mc Clane13 shared
- Julian Rood5 shared
- Jihong Li4 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Bruce A Mc Clane$13,048,720
- Jihong Li$859,097
- Julian Rood$693,763
- Yue Chen$146,276
- Mohammad Haroon Asif Choudry$1,176,755
Others in their field
Top investigators on “Mutant”
- Kc Kent Lloyd · University Of California At Davis$103,993,616
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Bruce A Beutler · Ut Southwestern Medical Center$34,438,453
- Oscar A. Carretero · Henry Ford Health System$33,594,856
- Stuart H Orkin · Children'S Hospital Boston$33,454,343
- Tracy T Batchelor · Dana-Farber Cancer Inst$31,851,614
Research focus
MutantIn VivoProductionClostridium PerfringensToxinInfectionBacteriaVirulenceIntestinesPathogenComplementAnimalsGenesIn VitroEnterotoxemiaEnteritisPathogenesisAnaerobic BacteriaLaboratoriesCellsMediatingOryctolagus CuniculusPathogenicityIntestinal Diseases
Grant awards (13)
Evaluating the role of branched chain amino acid transporters in Clostridium perfringens-induced gas gangrene in diabetic and normal mouse models$222,000
R21 · FY2024 · AI
Evaluating the role of branched chain amino acid transporters in Clostridium perfringens-induced gas gangrene in diabetic and normal mouse models$205,250
R21 · FY2023 · AI
NanI sialidase: Effects on Clostridium perfringens enterotoxin activity and contributions to C. perfringens type F infection$235,125
R21 · FY2021 · AI
NanI sialidase: Effects on Clostridium perfringens enterotoxin activity and contributions to C. perfringens type F infection$210,063
R21 · FY2020 · AI
Evaluating the Clostridium perfringens Agr-like Quorum Sensing System as a Therapeutic Target$235,113
R21 · FY2019 · AI
Evaluating the Clostridium perfringens Agr-like Quorum Sensing System as a Therapeutic Target$209,970
R21 · FY2018 · AI
Pathogenic Contributions of Clostridium perfringens NanI Sialidase$212,107
R21 · FY2017 · AI
Pathogenic Contributions of Clostridium perfringens NanI Sialidase$189,760
R21 · FY2016 · AI
Clostridium perfringens Type B-D Virulence Plasmids$397,821
R01 · FY2013 · AI
Clostridium perfringens Type B-D Virulence Plasmids$417,751
R01 · FY2012 · AI
Clostridium perfringens Type B-D Virulence Plasmids$416,537
R01 · FY2011 · AI
Clostridium perfringens Type B-D Virulence Plasmids$415,430
R01 · FY2010 · AI
Clostridium perfringens Type B-D Virulence Plasmids$433,750
R01 · FY2009 · AI